Caseware UK (AP4) 2024.0.164 2024.0.164 2025-12-31 2025-12-31 true 2025-01-01 false the sale and service of instruments for pharmaceutical and research organisations 50 50 true false 02209142 2025-01-01 2025-12-31 02209142 2024-01-01 2024-12-31 02209142 2025-12-31 02209142 2024-12-31 02209142 c:Director1 2025-01-01 2025-12-31 02209142 c:RegisteredOffice 2025-01-01 2025-12-31 02209142 d:Buildings d:LongLeaseholdAssets 2025-01-01 2025-12-31 02209142 d:Buildings d:LongLeaseholdAssets 2025-12-31 02209142 d:Buildings d:LongLeaseholdAssets 2024-12-31 02209142 d:FurnitureFittings 2025-01-01 2025-12-31 02209142 d:FurnitureFittings 2025-12-31 02209142 d:FurnitureFittings 2024-12-31 02209142 d:FurnitureFittings d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 02209142 d:OfficeEquipment 2025-01-01 2025-12-31 02209142 d:OfficeEquipment 2025-12-31 02209142 d:OfficeEquipment 2024-12-31 02209142 d:OfficeEquipment d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 02209142 d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 02209142 d:ComputerSoftware 2025-12-31 02209142 d:ComputerSoftware 2024-12-31 02209142 d:CurrentFinancialInstruments 2025-12-31 02209142 d:CurrentFinancialInstruments 2024-12-31 02209142 d:CurrentFinancialInstruments d:WithinOneYear 2025-12-31 02209142 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 02209142 d:ShareCapital 2025-12-31 02209142 d:ShareCapital 2024-12-31 02209142 d:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31 02209142 d:RetainedEarningsAccumulatedLosses 2025-12-31 02209142 d:RetainedEarningsAccumulatedLosses 2024-12-31 02209142 d:AcceleratedTaxDepreciationDeferredTax 2025-12-31 02209142 d:AcceleratedTaxDepreciationDeferredTax 2024-12-31 02209142 d:TaxLossesCarry-forwardsDeferredTax 2025-12-31 02209142 d:TaxLossesCarry-forwardsDeferredTax 2024-12-31 02209142 c:OrdinaryShareClass1 2025-01-01 2025-12-31 02209142 c:OrdinaryShareClass1 2025-12-31 02209142 c:OrdinaryShareClass1 2024-12-31 02209142 c:FRS102 2025-01-01 2025-12-31 02209142 c:Audited 2025-01-01 2025-12-31 02209142 c:FullAccounts 2025-01-01 2025-12-31 02209142 c:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 02209142 d:WithinOneYear 2025-12-31 02209142 d:WithinOneYear 2024-12-31 02209142 d:BetweenOneFiveYears 2025-12-31 02209142 d:BetweenOneFiveYears 2024-12-31 02209142 c:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 02209142 7 2025-01-01 2025-12-31 02209142 d:ComputerSoftware d:OwnedIntangibleAssets 2025-01-01 2025-12-31 02209142 e:PoundSterling 2025-01-01 2025-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 02209142 GILSON SCIENTIFIC LIMITED DIRECTOR'S REPORT AND FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 31 DECEMBER 2025
GILSON SCIENTIFIC LIMITED COMPANY INFORMATION
Director | Nicolas Paris
Registered number | 02209142
Registered office | 3b Humphrys Road
| Woodside Estate
| Dunstable
| England
| LU5 4TP
Independent auditors | Ecovis Wingrave Yeats LLP
| Chartered Accountants & Statutory Auditor
| 3rd Floor, Waverley House
| 7-12 Noel Street
| London
| W1F 8GQ
GILSON SCIENTIFIC LIMITED CONTENTS
| Page
Director's Report | 1 - 2
Balance Sheet | 3 - 4
Notes to the Financial Statements | 5 - 17
GILSON SCIENTIFIC LIMITED DIRECTOR'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2025 The director presents his report and the financial statements for the year ended 31 December 2025.
Director
The director who served during the year was:
Nicolas Paris
Director's responsibilities statement
The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable law and regulations. Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the director is required to: ∙select suitable accounting policies for the Company's financial statements and then apply them consistently; ∙make judgements and accounting estimates that are reasonable and prudent; ∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business. The director is responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable him to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Disclosure of information to auditors
The director at the time when this Director's Report is approved has confirmed that: ∙so far as he is aware, there is no relevant audit information of which the Company's auditors are unaware, and ∙he has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditors are aware of that information.
Small companies note
In preparing this report, the director has taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006. Page 1
GILSON SCIENTIFIC LIMITED DIRECTOR'S REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 This report was approved by the board on 9 July 2026 and signed on its behalf.
Nicolas Paris Director
Page 2
GILSON SCIENTIFIC LIMITED REGISTERED NUMBER: 02209142 BALANCE SHEET AS AT 31 DECEMBER 2025
|  | 2025 |  | 2024
Note |  | £000 |  | £000
Fixed assets |  |  |  |  |
Intangible fixed assets | 5 |  | - |  | 1
Tangible assets | 6 |  | 251 |  | 360
|  |  | 251 |  | 361
Current assets |  |  |  |  |
Stocks | 7 | 515 |  | 439 |
Debtors: amounts falling due within one year | 8 | 3,798 |  | 2,302 |
Cash at bank and in hand |  | 364 |  | 778 |
|  | 4,677 |  | 3,519 |
Creditors: amounts falling due within one year | 9 | (3,573) |  | (2,572) |
Net current assets |  |  | 1,104 |  | 947
Total assets less current liabilities |  |  | 1,355 |  | 1,308
Provisions for liabilities |  |  |  |  |
Deferred tax | 10 | (53) |  | (53) |
|  |  | (53) |  | (53)
Net assets |  |  | 1,302 |  | 1,255
Capital and reserves |  |  |  |  |
Called up share capital | 11 |  | 400 |  | 400
Profit and loss account | 12 |  | 902 |  | 855
|  |  | 1,302 |  | 1,255
Page 3
GILSON SCIENTIFIC LIMITED REGISTERED NUMBER: 02209142 BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2025 The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 9 July 2026.
Nicolas Paris
Director
The notes on pages 5 to 17 form part of these financial statements. Page 4
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025
1. | General information
Gilson Scientific Limited (the 'Company') is a private company limited by shares, incorporated in England and Wales, company number 02209142. The address of its registered office is 3b Humphrys Road, Woodside Estate, Dunstable, LU5 4TP. The principal activity of the Company is the sale and service of instruments for pharmaceutical and research organisations. The financial statements are prepared in Pounds Sterling as this is the functional currency and the currency of the primary economic environment in which the Company operates. Monetary amounts in these financial statements are rounded to the nearest thousand (£'000). 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The following principal accounting policies have been applied: Page 5
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 2.Accounting policies (continued)
| 2.2 | Going concern
The financial statements have been prepared on a going concern basis. In adopting this basis, the directors have considered the company’s financial position, cash flow forecasts and the wider group structure within which the company operates. The company is part of a European group of entities which operate on an integrated basis, with certain functions, costs and resources shared across group companies. As a result, the company is dependent on the continued financial and operational support of the wider group, including access to shared infrastructure, personnel and funding arrangements, in order to meet its obligations as they fall due. The company reported a net asset position of £1,302,000 at 31 December 2025 and reported a profit for the year of £47,000, however these figures are heavily influenced by group transactions and balances as can be seen in notes 8 and 9. The directors have prepared cash flow forecasts for a period of at least 12 months from the date of approval of these financial statements. These forecasts reflect the ongoing cost-sharing arrangements within the European group and the expectation that the company will continue to benefit from group support in respect of operational and funding requirements. The directors have received confirmation from the parent undertaking of the European sub-group, Gilson International B.V. that it will provide financial support to the company for a period of at least 12 months from the date of approval of these financial statements. This support is evidenced by a formal letter of support under which that undertaking has agreed to provide such financial assistance as is necessary to enable the company to meet its liabilities as they fall due. In addition, the directors have obtained a letter of support from the company’s ultimate parent undertaking, Gilson Scientific Inc, however, the directors’ assessment of going concern is primarily based on the expected support from the European group. Based on the forecasts prepared and the continued availability of group support, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements. Page 6
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 2.Accounting policies (continued)
| 2.3 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Sale of goods Revenue from the sale of goods is recognised when all of the following conditions are satisfied: ∙the Company has transferred the significant risks and rewards of ownership to the buyer; ∙the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the transaction; and ∙the costs incurred or to be incurred in respect of the transaction can be measured reliably. Rendering of services Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably.
| 2.4 | Intangible fixed assets
Intangible fixed assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years. The estimated useful lives range as follows:
|  |  |  | Computer software | - |  | 25% - 33% per annum
Amortisation is charged to administrative expenses in the Statement of Comprehensive Income. Page 7
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 2.Accounting policies (continued)
| 2.5 | Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. Depreciation is provided on the following basis:
|  |  |  | Leasehold improvements | - | 10% per annum
|  |  |  | Fixtures & fittings | - | 20% per annum
|  |  |  | Office equipment | - | 20% per annum
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss. Depreciation is charged to administrative expenses in the Statement of Comprehensive Income.
| 2.6 | Stocks
Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in the Statement of Comprehensive Income.
| 2.7 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.8 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value. Page 8
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 2.Accounting policies (continued)
| 2.9 | Financial instruments
The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Company's Balance Sheet when the Company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Basic financial assets Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments. Impairment of financial assets At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss. Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate. If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss. Financial liabilities Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities. Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted Page 9
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 2.Accounting policies (continued)
| 2.9 | Financial instruments (continued)
where the effect of discounting is immaterial. Debt instruments are subsequently carried at their amortised cost using the effective interest rate method. Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.
| 2.10 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
| 2.11 | Foreign currency translation
Functional and presentation currency The Company's functional and presentational currency is GBP. Transactions and balances Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges. Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Profit and Loss Account within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.
| 2.12 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument. Page 10
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 2.Accounting policies (continued)
| 2.13 | Operating leases
Rentals paid under operating leases are charged to the Statement of Comprehensive Income on a straight line basis over the lease term.
| 2.14 | Pensions
Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.
| 2.15 | Holiday pay accrual
A liability is recognised to the extent of any unused holiday pay entitlement which is accrued at the balance sheet date and carried forward to future periods. This is measured at the undiscounted salary cost of the future holiday entitlement so accrued at the balance sheet date.
| 2.16 | Current and deferred taxation
The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income. Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that: ∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and ∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met. Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date. Page 11
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 2.Accounting policies (continued)
| 2.17 | Provisions for liabilities
Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made. Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties. Increases in provisions are generally charged as an expense to profit or loss.
3. | Judgements in applying accounting policies and key sources of estimation uncertainty
Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Critical judgements in applying the entity’s accounting policies The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the reporting date and the amounts reported for revenues and expenses during the year. However, the nature of estimate means that actual outcomes could differ from those estimates. The key accounting judgements are detailed below: Tangible assets Tangible assets are depreciated over their useful lives taking into account residual values, where appropriate. The actual lives of assets and residual values are assessed annually and may vary depending on a number of factors. In re-assessing the assets' lives, factors such as technological innovation are taken into account. Stock provision All demo stock and all stock which has not had any sales in over a year is provided for as a stock provision. The stock provision at year-end was £676,000 and stock is including on the balance sheet net of this amount. Bad debt provision The Company makes an estimate of the recoverable value of trade and other debtors. When assessing impairment of trade and other debtors, management considers factors including the ageing profile of debtors and historical experience
4. | Employees
| The average monthly number of employees, including directors, during the year was 50 (2024 - 50).
Page 12
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025
5. | Intangible assets
|  | Computer software
|  | £000
| Cost |
| At 1 January 2025 | 123
| At 31 December 2025 | 123
| Amortisation |
| At 1 January 2025 | 122
| Charge for the year | 1
| At 31 December 2025 | 123
| Net book value |
| At 31 December 2025 | -
| At 31 December 2024 | 1
Page 13
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025
6. | Tangible fixed assets
|  | Leasehold improvements | Fixtures and fittings | Office equipment | Total
|  | £000 | £000 | £000 | £000
| Cost or valuation |  |  |  |
| At 1 January 2025 | 362 | 788 | 92 | 1,242
| Additions | - | 20 | 5 | 25
| At 31 December 2025 | 362 | 808 | 97 | 1,267
| Depreciation |  |  |  |
| At 1 January 2025 | 286 | 537 | 59 | 882
| Charge for the year | 36 | 89 | 9 | 134
| At 31 December 2025 | 322 | 626 | 68 | 1,016
| Net book value |  |  |  |
| At 31 December 2025 | 40 | 182 | 29 | 251
| At 31 December 2024 | 76 | 251 | 33 | 360
Page 14
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025
7. | Stocks
|  |  |  |  | 2025 | 2024
|  |  |  |  | £000 | £000
| Finished goods and goods for resale | 515 | 439
|  | 515 | 439
| Stock is shown net of a provision amounting to £676,000 (2024 - £737,000).
8. | Debtors
|  |  |  |  | 2025 | 2024
|  |  |  |  | £000 | £000
| Trade debtors | 727 | 920
| Amounts owed by group undertakings | 2,904 | 1,243
| Prepayments and accrued income | 167 | 139
|  | 3,798 | 2,302
| Amounts owed by group undertakings are interest free, unsecured and repayable on demand.
9. | Creditors: Amounts falling due within one year
|  |  |  |  | 2025 | 2024
|  |  |  |  | £000 | £000
| Trade creditors | 19 | 38
| Amounts owed to group undertakings | 2,774 | 1,776
| Corporation tax | 58 | 6
| Other taxation and social security | 305 | 302
| Other creditors | 23 | 22
| Accruals and deferred income | 394 | 428
|  | 3,573 | 2,572
| Amounts owed to group undertakings are interest free, unsecured and repayable on demand.
Page 15
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025
10. | Deferred taxation
|  | 2025
|  | £000
| At beginning of year | (53)
| At end of year | (53)
| The provision for deferred taxation is made up as follows:
|  |  |  |  | 2025 | 2024
|  |  |  |  | £000 | £000
| Accelerated capital allowances | (61) | (61)
| Short term timing differences | 8 | 8
|  | (53) | (53)
11. | Share capital
|  |  |  |  | 2025 | 2024
|  |  |  |  | £000 | £000
|  | Authorised |  |
|  | 500,000 (2024 - 500,000) Ordinary shares shares of £1.00 each | 500 | 500
|  | Allotted, called up and fully paid |  |
|  | 400,000 (2024 - 400,000) Ordinary shares shares of £1.00 each | 400 | 400
| Each Ordinary share has a voting right attached but no right to fixed income.
12. | Reserves
Profit and loss account This reserve comprises cumulative profits and losses of the Company.
13. | Pension commitments
The Company operates a defined contribution pension scheme. The pension cost charge represents contributions payable by the company and amounted to £274,000 (2024 - £318,000). Contributions totalling £22,619 (2024 - £22,103) were payable to the fund at the balance sheet end date and are included within creditors. Page 16
GILSON SCIENTIFIC LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025
14. | Commitments under operating leases
| At 31 December 2025 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:
|  |  |  |  | 2025 | 2024
|  |  |  |  | £000 | £000
| Not later than 1 year | 151 | 169
| Later than 1 year and not later than 5 years | 68 | 197
|  | 219 | 366
15. | Related party transactions
| The Company has taken advantage of the exemption available according with 'Section 33 'Related party disclosures' not to disclose transactions entered into between two or more members of a group that are wholly owned.
16. | Controlling party
The immediate parent company at the year end was Life Science Supplies Ltd, a company incorporated in England and Wales. The registered office address is 3b Humphrys Road, Woodside Estate, Dunstable, LU5 4TP. Subsequent to the year end, Life Science Supplies Ltd was struck off and dissolved. The smallest group to prepare consolidated accounts in which this entity is included is Gilson Inc., a company incorporated in the United States of America. The registered address of Gilson Inc. is 3000 Parmenter Street, Middleton, Wisconsin 53562-0828, USA. The ultimate controlling party is considered to be Dr. Robert Gilson by virtue of his majority shareholding.
17. | Auditors' information
The auditors' report on the financial statements for the year ended 31 December 2025 was unqualified. The audit report was signed on 9 July 2026 by Sally Casson (Senior Statutory Auditor) on behalf of Ecovis Wingrave Yeats LLP.
Page 17